glp 1 oral drug GLP-1 Therapy: Pills vs Injections? Oral GLP-1: A Needle-Free Solution

The mutational constraint spectrum quantified from variation in 141,456 humans

Innovation will broaden choice: oral therapies, triple agonists, combination treatments and agents designed to improve tolerability will increase diversity and competition

Dizziness , headaches , and fatigue appear in the clinical data as well

Many people find that keeping fat intake lower reduces these issues

doi: 10.1080/00325481.2021.2002616

We excluded 1) those with diagnoses of AF, atrial tachycardia, ventricular tachycardia, ventricular fibrillation, mechanical valve, hyperthyroidism, or mitral stenosis before or on the index date, 2) those with cardiac events (i.e., myocardial infarction, percutaneous intervention, valve/bypass surgery) in the preceding 3 months, 3) those currently receiving antiarrhythmic medications (e.g., amiodarone, dronedarone, flecainide, propafenone, or dofetilide) on the index date, 4) those who used insulin within one year prior or on the index date, and 5) those who do not have hemoglobin A1C (HbA1c) within one year prior or on the index date (eFigure 1)